 So I wanted to sort of flag, too, there was a little bit of the discussion about the DEA. You know, unlike GLP-1s, which are really, you know, sort of ramping up production, that's right, the Ozempic, manufacturers have a great incentive to expend capacity. And so they're investing billions of dollars, and it's hard for them to ramp up fast enough.